{"name":"Lynk Pharmaceuticals Co., Ltd","slug":"lynk-pharmaceuticals-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"LNK01001","genericName":"LNK01001","slug":"lnk01001","indication":"Cancer (specific indication under Phase 3 evaluation)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"LNK01004 ointment 1.0%","genericName":"LNK01004 ointment 1.0%","slug":"lnk01004-ointment-1-0","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"LNK01001","genericName":"LNK01001","slug":"lnk01001","phase":"phase_3","mechanism":"LNK01001 is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity.","indications":["Cancer (specific indication under Phase 3 evaluation)"],"catalyst":""},{"name":"LNK01004 ointment 1.0%","genericName":"LNK01004 ointment 1.0%","slug":"lnk01004-ointment-1-0","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOVExJQ0tfMFJObmFMTkhzZ1FvYlFwN2VsVFN6bUQ5b3ZzOHBtd3VuUjE0Rjltc2M0emFHVG92TmRYUE1ZVmVqYW04ZVhuR1IyWHhSdXBKUGlnRnJldUdCbXUzYURucWRnbFR4SDZaajFmYXlyMUIxdmVieWRKdUtmM3RxOS1IMTgyb0V4bWt3Q1hNOXBpVmpudg?oc=5","date":"2026-03-20","type":"pipeline","source":"openPR.com","summary":"Myelofibrosis Pipeline 2026: Therapies Under Investigation, - openPR.com","headline":"Myelofibrosis Pipeline 2026: Therapies Under Investigation,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNQmtKU0Q5c25lMl9LblRFeUZuSTNBWmYxOXlmV0VfSGVCOGJRMEp3U3lIN2lIMkxLek56STU1b1VfREVWTXdVckxCTmVhU05VSnlSM2NUandmSWlyNkpuOHUwY1NUZGFjdVJ4Tm4yRWdma05KcUl6NVNkSDZmaEdZWkFTQ3FJZ2ppSWpCNjV1MFNkczhJaU5XTlZiUlRqNXA4VFBfT3FtU0xXT3VjY0hHa2k2cGlPVEFMNTdzM0FrdVJJRFdIOHRMcEg4Y2h4bEc2TnVRMzdfTHI?oc=5","date":"2026-01-13","type":"trial","source":"BioPharma APAC","summary":"Lynk Pharmaceuticals Delivers Breakthrough Phase Three Win For Oral Rheumatoid Arthritis Therapy - BioPharma APAC","headline":"Lynk Pharmaceuticals Delivers Breakthrough Phase Three Win For Oral Rheumatoid Arthritis Therapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1MUHEwRzc2d2luYWdIWlQ4ZUliWWR6QTJRdUZHYmw1dkxOTnZYQkptd0xCOVBjb2hkSGc0MUExRlpVd0g1bjg3M1FIa0pCc2FOVUN6MzlONnhZQzVhTGtTWmJhbnJZeHM2U1dYRUlUWV9XVGRYOWVfOA?oc=5","date":"2026-01-03","type":"patent","source":"Patently-O","summary":"Supreme Court’s January 2026 IP Docket: Hikma Leads a Small but Significant Field - Patently-O","headline":"Supreme Court’s January 2026 IP Docket: Hikma Leads a Small but Significant Field - Patently","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQRmhzWnk5dW1idzVzUHVyMGN1bEY1REdGeURzbTlGa1VkeVhDWElIUlpTcDZJMUdiUlNhMmRoYW1pSmM1MW9DN0E3T2lGUXdrcjdZeTVCYU1YemdUa2NXMkZuZ01fX0tmWTVMVEZTUXVYZE9WR1liSy1TTWFxbE1zUnhqRnJPM2o5SXRqOURZelk5Q1hGQ01pRHdkNWNzTmMyelJGb1JnYw?oc=5","date":"2025-12-11","type":"pipeline","source":"BioWorld News","summary":"Formation loads new Bleecker division with Lynk’s TYK2 inhibitor - BioWorld News","headline":"Formation loads new Bleecker division with Lynk’s TYK2 inhibitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE50UG5DMk5zZnJYTVVEN2g4aFY5aEV5QTRESzNpWnJlYXBhLWpPZ3g0YWtUd2hsWlJOeW01SlM5dDBIaVJXQkpXalRQa09NYlMyUEtKd2JxT0RzSGprWkNJc1paV3ZvRGhhVTRRM0kwd0s4SzVR?oc=5","date":"2025-12-11","type":"pipeline","source":"Pharmaceutical Technology","summary":"Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor - Pharmaceutical Technology","headline":"Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQX1plRzhnRjVSdXpZeGZqUjhEa1pXNUlCRjc2VEIzS21aSVU3TkY2dFVtLVlCcU1GR0FyZml3a0YyV0lTMG16dC1aQXlvQUIwWEFKUUYzMURIcGxlWFhlc1NPZGNxRklYZDhkcDVBY0RKTFVtSndxMnZGcUR5N3ZjeXNGNFBfRHBoWDdvNFJEZGV1ZTBEMl9wNTdLOHU1SDZNc1FMbE5NYlc3YzdCRmpaVGpVRQ?oc=5","date":"2025-12-10","type":"deal","source":"The Pharma Letter","summary":"Formation Bio licenses CNS penetrant TYK2 inhibitor from Lynk Pharma - The Pharma Letter","headline":"Formation Bio licenses CNS penetrant TYK2 inhibitor from Lynk Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOQll4amU0dXVFaFBobXgyd2EtNHRoWG5sdTdfUHVfMXhxbXB0aF9YNHBzYms4eF9LcksyeHNMYXlHM0lsckpScTVkZEkzZ05oRkJZdGlFTFg5a1piS051NmpIdXlRaFhySzV4dXdTOUtJTDVVYUNxV29FUWQtOWhEN3lxOUZva2NILXpXTA?oc=5","date":"2025-12-01","type":"regulatory","source":"Yahoo Finance","summary":"Lynk Pharmaceuticals Announces FDA IND Approval of Its Allosteric TYK2 Inhibitor LNK01006 - Yahoo Finance","headline":"Lynk Pharmaceuticals Announces FDA IND Approval of Its Allosteric TYK2 Inhibitor LNK01006","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxPTmR3WE1PZ1FPVWRHaXJ2X3VxVlFYNnItTVZyaURZUUFZSjlkYlowMFp5T1RwLU5RbUFmalg5Nm1BNjNueFIzT0RkMVhIMm9wZTdfRjB1NU1xejR6M0J5TkFZSDlEdmNLSTZBVGthYk5YTnZ0LUJtajd2dkdSWkcyUHBSckFtTWxaWGlCX0xoV01VQV96REl5a1dfM2xQTEFpYlkyVllneXVNMWMxaVBDNXI0MjQ0SkdkWmJSSDNMSFlNS1Y0RTZIcTJ2X0VVLUhueGtGMy1pSy1VMk4xcm1wVHRQaWsybDZNd2M1NUYyVnc3YUN4M1VCYmNCV0FLakxhazBV?oc=5","date":"2025-09-18","type":"pipeline","source":"PR Newswire","summary":"Formation Bio Expands Leadership Team With Top Biotech and Pharma Executives to Accelerate AI-Driven Drug Development - PR Newswire","headline":"Formation Bio Expands Leadership Team With Top Biotech and Pharma Executives to Accelerate AI-Driven Drug Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxQSDRlcTFteFU3MEkzSnNQdTRXV2RZMTZ4RGk1ZTkyblltZTI1SDBBWjkzUnhNVmpTRkM1dDk0YnA3VWlJcVZnQ0pMMllPQ3RkOENmYkRxYldTcVpLQkh6ZEYxWUVUSlNXWVZsS3ZnazZRR3BzSllPNUFvM1hTRXdudjZacm91QkFGWkluWlZOdThaLUpXU2QwVS1JV0dzdFZndVJHVHdEMVJ6UkpxVUUwUFdXRENxLUtOTjdSMGdqWHdrNUkwVTBPdjlQazB5Z3hjTktIbXROcmt0Uk5XNThfVnRYVF9KQlY2bVhCUW5sRGdXUVdiTE9pdGFVRy0xVVliNjNMZFRfblpfVkdsSENjQ2RLdThzczQ?oc=5","date":"2025-03-04","type":"regulatory","source":"PR Newswire UK","summary":"Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight - PR Newswire UK","headline":"Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPUHhxaGFRWDg0OGxIcXBWWlZreTFab01VRDhtSF9XVjdiQjZhcG5oYWttTmt2bVBvM3VFNWJzalMyWlc0Wms0a0lzX2l3Mm5YcExCN0hLWkktd1ZPcnF3UFNyUDZURksxeHp6eTRCUjc0V1BXTW9HZERUU09IYmZ0RUFtYTNVWDZkWUFsYVplOWFXbHE3R2xpUk9FN0Y1eXBGYUZkZU5pX2xsUTBOQVpDc21GSTNJS2ZIa3JkU0ktRlI4SUZuU1RTQWFNNlJ2bzA2UnBPQkZRaEhIR3FXN2tpUHIzN0xfSEZ5SUowNmVKZXZ4LVFsZmRj?oc=5","date":"2025-02-26","type":"pipeline","source":"PR Newswire","summary":"The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight - PR Newswire","headline":"The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxORnViXzB3VVFUSjAxaVdiMDNFS2d3b1BJallZZS1LVTBrU3NDampweURKeGVtaE9oS2FPc0M0MXpYdDdRSE8tTHNCZlVFSEk1RTdrU1Qxd3p4eGMxNXlpVWlHUTlrNjV5RkJHdjhWajVnSGxzcm9wV0JkMWtBVXZwQ29qcGZlVVdIcURDdm9MbEFuZ3lENTFua2dRQlUydTZjMnVFS2FXS2I0OUpSU2R0UzBnWmZaVlZza1lnSU5YMm5vU2dBeW81bGN4cW9UY1QtdkNCMWxqMUF5WHZGWVYydDc5RWhHWUFSV0FNZTNPOFgxdw?oc=5","date":"2025-02-20","type":"regulatory","source":"globenewswire.com","summary":"BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - globenewswire.com","headline":"BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQc2RNb3BwcDdsZEJzRHhXSVduZmZjeTZpZGZ6eUFYT1FGbWh3aUFiMUVkZGVqZVU1d2QzbEsyQ05qNFFlU2lKZklaOGVFeUxPZXZKZGNSY1hucHZBaGJYYnc1OFZlU0phcXhRUkV4Uzh6bktxTXFQaWI5NGdDdk0tQ2wxX3JNc3M1S3pVcUlTSXNRV2pyTXUzS204cF9fUVd1TWtlNW1pb3ZHZHVSR09MZnVKTFRlZHpEVWJGTnZ1TUd3dzNwSmEwN2J6U3JBcE9ZRWNndGp0MEhPQnp2Q3c?oc=5","date":"2024-03-22","type":"trial","source":"BioPharma APAC","summary":"Lynk Pharmaceuticals Initiates Pivotal Phase III Trial for Groundbreaking Atopic Dermatitis Treatment - BioPharma APAC","headline":"Lynk Pharmaceuticals Initiates Pivotal Phase III Trial for Groundbreaking Atopic Dermatitis Treatment","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}